C WorldWide Group Holding A S Has $38.55 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

C WorldWide Group Holding A S grew its position in Edwards Lifesciences Co. (NYSE:EW) by 5.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 505,565 shares of the medical research company’s stock after buying an additional 26,169 shares during the period. Edwards Lifesciences accounts for approximately 0.5% of C WorldWide Group Holding A S’s investment portfolio, making the stock its 22nd largest holding. C WorldWide Group Holding A S owned approximately 0.08% of Edwards Lifesciences worth $38,549,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Caprock Group LLC boosted its position in shares of Edwards Lifesciences by 4.8% in the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock worth $597,000 after purchasing an additional 392 shares during the last quarter. Oak Thistle LLC acquired a new position in Edwards Lifesciences in the third quarter valued at about $700,000. Czech National Bank boosted its holdings in Edwards Lifesciences by 48.1% during the third quarter. Czech National Bank now owns 106,252 shares of the medical research company’s stock worth $7,361,000 after buying an additional 34,487 shares during the last quarter. Asset Management One Co. Ltd. boosted its holdings in Edwards Lifesciences by 0.5% during the third quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company’s stock worth $22,393,000 after buying an additional 1,622 shares during the last quarter. Finally, Connecticut Wealth Management LLC grew its position in shares of Edwards Lifesciences by 66.7% during the 3rd quarter. Connecticut Wealth Management LLC now owns 9,960 shares of the medical research company’s stock worth $690,000 after buying an additional 3,985 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock valued at $17,166,254 in the last quarter. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW traded down $1.58 during midday trading on Friday, reaching $86.43. The stock had a trading volume of 4,979,943 shares, compared to its average volume of 2,883,164. The firm has a market cap of $52.02 billion, a PE ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. The firm has a 50 day simple moving average of $90.28 and a 200-day simple moving average of $78.85. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.34% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on EW shares. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research note on Friday. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Mizuho raised their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Finally, Piper Sandler increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $93.33.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.